140 related articles for article (PubMed ID: 20729815)
1. A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Zuo Z; Jones D; Yao H; Thomas DA; O'Brien S; Ravandi F; Kantarjian HM; Abruzzo LV; Medeiros LJ; Chen SS; Luthra R
Mod Pathol; 2010 Nov; 23(11):1524-34. PubMed ID: 20729815
[TBL] [Abstract][Full Text] [Related]
2. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
[TBL] [Abstract][Full Text] [Related]
3. Philadelphia Chromosome-like Acute Lymphoblastic Leukemia.
Pui CH; Roberts KG; Yang JJ; Mullighan CG
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):464-470. PubMed ID: 28842136
[TBL] [Abstract][Full Text] [Related]
4. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
[TBL] [Abstract][Full Text] [Related]
5. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance.
Iacobucci I; Lonetti A; Messa F; Cilloni D; Arruga F; Ottaviani E; Paolini S; Papayannidis C; Piccaluga PP; Giannoulia P; Soverini S; Amabile M; Poerio A; Saglio G; Pane F; Berton G; Baruzzi A; Vitale A; Chiaretti S; Perini G; Foà R; Baccarani M; Martinelli G
Blood; 2008 Nov; 112(9):3847-55. PubMed ID: 18650450
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.
DeBoer R; Koval G; Mulkey F; Wetzler M; Devine S; Marcucci G; Stone RM; Larson RA; Bloomfield CD; Geyer S; Mullighan CG; Stock W
Leuk Lymphoma; 2016 Oct; 57(10):2298-306. PubMed ID: 26892479
[TBL] [Abstract][Full Text] [Related]
7. The biology of Philadelphia chromosome-like ALL.
Roberts KG
Best Pract Res Clin Haematol; 2017 Sep; 30(3):212-221. PubMed ID: 29050694
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and outcomes of unrelated bone marrow transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) pre-treated with tyrosine kinase inhibitors.
Yoshimura T; Nakane T; Hirose A; Koh H; Nakamae M; Aimoto M; Nishimoto M; Hayashi Y; Terada Y; Nakamae H; Hino M
Osaka City Med J; 2013 Jun; 59(1):9-21. PubMed ID: 23909077
[TBL] [Abstract][Full Text] [Related]
10. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
[TBL] [Abstract][Full Text] [Related]
11. IK6 isoform with associated cytogenetic and molecular abnormalities in Chinese patients with Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Yao L; Cen J; Chen S; Shen H; Chen Y; He J; Chen Z
Leuk Lymphoma; 2013 Aug; 54(8):1626-32. PubMed ID: 23150929
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Piccaluga PP; Paolini S; Martinelli G
Cancer; 2007 Sep; 110(6):1178-86. PubMed ID: 17701954
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of cytogenetic heterogeneity in Philadelphia chromosome positive (Ph+) adult B cell acute lymphoblastic leukemia following tyrosine kinase inhibitors and chemotherapy regimens.
Jain P; Gu J; Kanagal-Shamanna R; Tang Z; Patel KP; Yao H; Fang L; Bao HY; Liu CH; Lin P; Medeiros LJ; Lu X
Leuk Res; 2019 Sep; 84():106176. PubMed ID: 31279181
[TBL] [Abstract][Full Text] [Related]
14. Ikaros deletions in BCR-ABL-negative childhood acute lymphoblastic leukemia are associated with a distinct gene expression signature but do not result in intrinsic chemoresistance.
Vitanza NA; Zaky W; Blum R; Meyer JA; Wang J; Bhatla T; Morrison DJ; Raetz EA; Carroll WL
Pediatr Blood Cancer; 2014 Oct; 61(10):1779-85. PubMed ID: 24976218
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
[TBL] [Abstract][Full Text] [Related]
18. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors.
Abou Dalle I; Kantarjian HM; Short NJ; Konopleva M; Jain N; Garcia-Manero G; Garris R; Qiao W; Cortes JE; O'Brien S; Kebriaei P; Kadia T; Jabbour E; Ravandi F
Am J Hematol; 2019 Dec; 94(12):1388-1395. PubMed ID: 31595534
[TBL] [Abstract][Full Text] [Related]
19. IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia.
Moorman AV; Schwab C; Ensor HM; Russell LJ; Morrison H; Jones L; Masic D; Patel B; Rowe JM; Tallman M; Goldstone AH; Fielding AK; Harrison CJ
J Clin Oncol; 2012 Sep; 30(25):3100-8. PubMed ID: 22851563
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Milone JH; Enrico A
Leuk Lymphoma; 2009 Dec; 50 Suppl 2():9-15. PubMed ID: 20017606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
